Atossa Therapeutics, Inc.
ATOS
Last
$2.44
Day
+0.8%
1y
-86.3%
5y
-94.7%
52w
-87.5%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1132d
EMA 21
2.32
EMA 50
2.44
EMA 200
4.77
20d high
-5.3%
5y high
-95.2%
5y range
2th
Positions held
Your positionsATOS isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
24
Hold
swing
Signal
Buy
Target
$2.72
Stop
$2.17
Stop distance
11.1%
Target vs last
+11.5%
Fundamentals
| Market cap | $24.15M | Enterprise value | -$1.94M | Trailing P/E | — | Forward P/E | -0.73 |
| PEG | — | Price / book | 0.90 | Beta | 1.28 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -89.2% | ROA | -50.7% | Debt / equity | — |
| Current ratio | 5.69 | Free cash flow | -$23.33M | Analyst recommendation | strong_buy | Mean target | $19.00 |
| 52w high | $18.00 | 52w low | $1.70 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$8.5M | -$9.6M | -$10.9M | -$8.7M | -$8.4M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$8.7M | -$9.9M | -$11.4M | -$9.3M | -$9.0M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$34.8M | -$25.5M | -$30.1M | -$27.0M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$37.1M | -$27.6M | -$31.4M | -$27.7M |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-30 · Atossa plans shareholder stake in potential PRV proceeds
2026-08-14 · ATOS: Multiple Catalysts Converge in 2H26
2026-08-07 · Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
2026-07-21 · Straight Out Of A Soap Opera: Biotech Exec Arrested After 21 Years On The Run
Price (daily)
Full chart · RSI · MACD · patternsATOS · daily+7.6% over 14 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin